In the last trading session, 1.17 million shares of the Fulcrum Therapeutics Inc (NASDAQ:FULC) were traded, and its beta was 2.48. Most recently the company’s share price was $7.85, and it changed around $0.83 or 11.82% from the last close, which brings the market valuation of the company to $423.73M. FULC currently trades at a discount to its 52-week high of $10.13, offering almost -29.04% off that amount. The share price’s 52-week low was $2.32, which indicates that the current value has risen by an impressive 70.45% since then. We note from Fulcrum Therapeutics Inc’s average daily trading volume that its 10-day average is 0.64 million shares, with the 3-month average coming to 598.50K.
Fulcrum Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 2.00. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 2 recommended FULC as a Hold, whereas 3 deemed it a Buy, and 1 rated it as Underweight.
Fulcrum Therapeutics Inc (NASDAQ:FULC) trade information
Instantly FULC has showed a green trend with a performance of 11.82% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 7.93 on recent trading dayincreased the stock’s daily price by 1.01%. The company’s shares are currently up 27.54% year-to-date, but still up 14.10% over the last five days. On the other hand, Fulcrum Therapeutics Inc (NASDAQ:FULC) is 10.41% up in the 30-day period. We can see from the shorts that 5.82 million shares have been sold at a short interest cover period of 10.67 day(s).
The consensus price target as assigned by Wall Street analysts is $10.5, which translates to bulls needing to increase their stock price by 25.24% from its current value. Analyst projections state that FULC is forecast to be at a low of $9 and a high of $12.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 54.59%.
FULC Dividends
Fulcrum Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-May-01.
Fulcrum Therapeutics Inc (NASDAQ:FULC)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.82% of Fulcrum Therapeutics Inc shares, and 96.20% of them are in the hands of institutional investors. The stock currently has a share float of 97.98%. Fulcrum Therapeutics Inc stock is held by 159.0 institutions, with RA CAPITAL MANAGEMENT, L.P. being the largest institutional investor. By 2024-06-30, it held 18.6636% of the shares, which is about 11.61 million shares worth $71.98 million.
RTW INVESTMENTS, LP, with 9.3979% or 5.85 million shares worth $36.24 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
